CCL26 and Alzheimer disease: Additionally, to follow up on these biomarker candidates, their ability to discriminate AD from other causes of dementia needs to be examined; indeed, several of these markers have already shown promise for distinguishing AD from frontotemporal lobar degeneration (cystatin C [20], eotaxin-3 [18], and HGF [18]).